HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hirschowitz, E. A. Articles by Yannelli, J. R. Search for Related Content PubMed PubMed Citation Articles by Hirschowitz, E. A. Articles by Yannelli, J. R.

Immunotherapy for Lung Cancer

¹ Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Kentucky, Chandler Medical Center, Lexington, Kentucky; ² Lexington Veterans Administration Medical Center, Lexington, Kentucky; and ³ Department of Microbiology, Immunology, and Human Genetics, University of Kentucky, Lexington, Kentucky

Correspondence and requests for reprints should be addressed to Edward A. Hirschowitz, M.D., Division of Pulmonary and Critical Care Medicine, University of Kentucky, Chandler Medical Center, 740 S. Limestone, Room K528, Lexington, KY. E-mail: eahirs2{at}uky.edu

ABSTRACT

Immunotherapy is a conceptually attractive approach, because it is highly specific and can deal with disseminated disease with minimal impact on normal tissues. Ability to induce antigen-specific immune responses in patients with lung cancer is now well established in early-phase clinical trials using a variety of immunotherapeutic approaches. Although no immunotherapy is likely to be a panacea, randomized phase IIB studies offer promise of therapeutic activity in both early- and late-stage lung cancer. This review will cover basic concepts of immunotherapy, provide perspective on vaccine development, and update the status of ongoing clinical trials in lung cancer.

Key Words: immunotherapy • vaccines • lung cancer • clinical trials